ROSUVASTATIN FOR REDUCTION OF MYOCARDIAL DAMAGE AND SYSTEMIC INFLAMMATION DURING CORONARY ANGIOPLASTY - The REMEDY Study - ND

CARDIOLOGIA UNIVERSITARIA - OSPEDALE CLINICIZZATO SS. ANNUNZIATA - VIA DEI VESTINI - 66013 CHIETI0 个研究点开始时间: 2009年11月5日最近更新: 2012年3月19日

适应症

试验速览

暂无简介。

•Inclusion criteria will be the presence of suspected CAD for which an indication to PCI is given. This study will therefore include both patients with stable CAD, and stable post-acute coronary syndromes (ACS), both with ST-segment elevation (STEMI) and without ST-segment elevation (NSTE-ACS) patients, provided that markers of myocardial necrosis (CK-MB, troponins) are stabilized (i.e., with variations <20% in two consecutive measurements obtained at ≥6 h time distance before PCI, according to the universal definition of peri-procedural myocardial infarction43). Randomization will be performed independent of the knowledge of coronary anatomy. Outcome evaluation will be however primarily performed on patients randomized and receiving a PCI.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range

•Exclusion criteria will be:
•oany previously known increase in liver enzymes (AST, ALT) ascribed to liver dysfunction at baseline;
•ohistory of liver toxicity or myopathy on previous treatment with statins;
•oleft ventricular ejection fraction <30%;
•orenal insufficiency, with creatinine >2 mg/dL at baseline;
•opregnant women.

发起方

CARDIOLOGIA UNIVERSITARIA - OSPEDALE CLINICIZZATO SS. ANNUNZIATA - VIA DEI VESTINI - 66013 CHIETI